Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Cue Biopharma (Nasdaq: CUE) will receive a $7.5 million preclinical milestone payment from its collaboration and license agreement with Boehringer Ingelheim after selection and approval of the first compound for lead optimization.

Rhea-AI Summary

Cue Biopharma (Nasdaq: CUE) will receive a $7.5 million preclinical milestone payment from its collaboration and license agreement with Boehringer Ingelheim after selection and approval of the first compound for lead optimization. The company expects the payment in May 2026. The multi-year collaboration could yield up to $337.5 million in additional milestone payments plus royalties and allows expansion into B cell-targeting bispecifics. Cue is advancing its lead autoimmune asset, CUE-401, toward the clinic while Boehringer Ingelheim will further develop CUE-501 under the agreement.

Positive

• $7.5 million preclinical milestone payment expected in May 2026
• Eligible for up to $337.5 million in additional milestone payments plus royalties
• Multi-year collaboration expands R&D into B cell-targeting bispecifics
• CUE-401 progressing toward clinical development

Negative

• Future payments are milestone-dependent and not guaranteed

Argus Apr 8 session

+45.48% close to close Open Argus

Details

News Market Reaction – CUE

On Apr 8, the day this news came out, CUE closed 45.48% above the previous close.

Data tracked by StockTitan Argus for the Apr 8 session.

Market Context

On Apr 8, the day this news came out, the stock closed 45.5% above the previous close. A strong posi...

Analysis

On Apr 8, the day this news came out, the stock closed 45.5% above the previous close. A strong positive reaction aligns with the concrete validation and cash inflow from this Boehringer Ingelheim milestone. The $7.5M payment, plus eligibility for up to $337.5M in future milestones, reinforces the partnered CUE-501 program alongside CUE-401’s progress. However, an effective $300M shelf and historical selling on good news suggest that financing activity or profit-taking could temper sustainability of large gains.

Key Figures

Preclinical milestone payment: $7.5M Future milestones eligibility: $337.5M Payment timing: May 2026 +2 more

Preclinical milestone payment

$7.5M

Milestone from Boehringer Ingelheim collaboration, expected May 2026

Future milestones eligibility

$337.5M

Additional research, development and commercial milestone payments potential

Payment timing

May 2026

Expected receipt of $7.5M preclinical milestone payment

Shelf registration size

$300,000,000

S-3 filed Mar 17, 2026 for multiple security types

ATM capacity

$12,666,282

At-the-market sales agreement under S-3 with Jefferies

Historical Context

5 past events · Latest: Mar 27

5 events

1. Mar 27

   CEO transition

   24h Move

   -5.6%

   Interim CEO Lucinda Warren appointed after prior CEO resignation.

2. Mar 26

   R&D day announcement

   24h Move

   -5.0%

   Announcement of virtual R&D Day focused on CUE-401 research.

3. Mar 16

   Earnings and updates

   24h Move

   -12.8%

   Higher collaboration revenue, ImmunoScape deal, cash and pipeline progress.

4. Mar 9

   New CUE-401 data

   24h Move

   +0.4%

   New in vitro data on CUE-401’s immune-modulating design at WIRM.

5. Feb 17

   Preclinical safety data

   24h Move

   -5.1%

   Preclinical safety and tolerability data for CUE-401 with no adverse events.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

preclinical milestone, lead optimization, t cell-mediated, bispecific molecule, +2 more

6 terms

preclinical milestone medical

"Preclinical milestone for selection and approval of first compound for lead optimization"

A preclinical milestone is a specific, measurable achievement reached during laboratory or animal testing of a drug, device, or therapy before it is tried in humans. Investors pay attention because these milestones reduce scientific uncertainty, unlock staged payments from partners or investors, and increase the project’s value much like a working prototype test increases confidence that a product can be commercialized.

lead optimization medical

"selection and approval of its first compound for lead optimization"

A stage in drug discovery where promising chemical or biological candidates (“leads”) are systematically changed and tested to make them more potent, safer, longer-lasting, and easier to turn into a medicine. Think of it like sharpening and tuning a prototype tool until it reliably does the job. For investors, successful lead optimization raises the chance a candidate will enter clinical trials, shortens development time, reduces later-stage failure risk, and increases potential value for partners or buyers.

t cell-mediated medical

"intended mechanistic effect of CUE-501 for T cell-mediated targeted depletion"

T cell-mediated describes a biological effect that is driven by T cells, a type of immune cell that seeks out and destroys infected or abnormal cells. Think of T cells as security guards: when a treatment or disease triggers them, the result can be a targeted attack on harmful cells (useful for vaccines or cancer therapies) or collateral damage to healthy tissue (a safety risk), so investors watch this term for clues about a therapy’s effectiveness, side effects and regulatory outlook.

bispecific molecule medical

"further develop CUE-501, a bispecific molecule intended for autoimmune"

A bispecific molecule is an engineered therapeutic that can bind two different biological targets at once, often two proteins on the same or different cells. Think of it as a two-ended connector that brings components together—such as a diseased cell and an immune cell—to trigger a specific biological response. For investors, bispecifics can offer the potential for stronger or more precise effects than single-target drugs, but they also add development complexity and regulatory risk.

autoimmune and inflammatory diseases medical

"specific B cells to address autoimmune and inflammatory diseases"

Autoimmune and inflammatory diseases are conditions in which the body's defense system mistakenly attacks healthy tissue or stays active too long, causing pain, swelling, organ damage or chronic symptoms—think of the immune system as an overzealous security guard that faults the building it is protecting. For investors, these diseases matter because they drive demand for long-term treatments, diagnostics and therapies, influence regulatory approval and reimbursement risks, and shape companies’ revenue and growth prospects in healthcare markets.

B cells medical

"targeted depletion of specific B cells to address autoimmune"

B cells are a type of white blood cell that act like antibody factories and memory keepers for the immune system: they produce proteins that recognize and neutralize specific pathogens and remember past infections or vaccines. Investors watch B-cell activity because many drugs and vaccines work by boosting, suppressing, or measuring these cells—so changes in B-cell data can signal a therapy’s potential effectiveness, safety profile, or market opportunity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Preclinical milestone for selection and approval of first compound for lead optimization has been achieved
  
• Further development validates the potential intended mechanistic effect of CUE-501 for T cell-mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases

BOSTON, April 08, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage memory T cell subsets to deplete pathogenic B cells for the potential treatment of autoimmune and inflammatory diseases, today announced that it will receive a $7.5 million preclinical milestone payment under its collaboration and license agreement with Boehringer Ingelheim following Boehringer Ingelheim’s selection and approval of its first compound for lead optimization. The Company expects to receive the payment in May 2026.

“We are very pleased to have achieved this critical preclinical milestone through our strategic research collaboration with Boehringer Ingelheim,” said Lucinda Warren, interim president and chief executive officer of Cue Biopharma. “This is a very exciting time for the Company as we progress our lead autoimmune asset, CUE-401, toward the clinic and reach this important milestone in our collaboration with Boehringer Ingelheim to further develop CUE-501, a bispecific molecule intended for autoimmune and inflammatory diseases.”

Under the terms of the collaboration and license agreement with Boehringer Ingelheim, Cue Biopharma’s technology will be leveraged to further research and advance the development of the candidate molecule. The terms of the multi-year collaboration also include the ability of the parties to expand research and development into various B cell targeting bispecifics encompassing autoimmune diseases.

Pursuant to the terms of the collaboration, Cue Biopharma is also eligible to earn, in addition, up to approximately $337.5 million in additional research, development and commercial milestone-based payments as well as royalty payments on net sales.

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT^® (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system without the adverse effects of broad systemic immune modulation. CUE-401, the company’s lead autoimmune asset, is designed to act mechanistically both as a regulator of proinflammatory mechanisms, and as a master switch for regulatory T cell (Treg) differentiation to induce tolerance. It is a highly innovative, tolerogenic bifunctional molecule combining a TGF-beta breathing-mask moiety with Cue Biopharma’s clinically validated interleukin 2 (IL-2) mutein in a single injectable biologic.

Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.

For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: timing of a preclinical milestone payment expected to be received by the Company; the Company’s belief regarding the potential benefits and applications of its drug candidates and programs, including pursuant to its collaboration and license agreement with BI and the Company’s plans to further advance its differentiating Immuno-STAT^® platform and lead autoimmune asset, CUE-401, including the company’s plans to move CUE-401 toward the clinic; and the Company’s business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “promise” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the Company’s ability to maintain its collaboration with ImmunoScape; the Company’s limited operating history, limited cash and a history of losses; the Company’s ability to obtain adequate financing to fund its business operations in the near term and successfully remediate its current “going concern” determination that it does not have sufficient capital on hand to continue operations beyond the next twelve months; the Company’s ability to achieve profitability; potential setbacks in the Company’s research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the Company’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; its ability to secure required U.S. Food and Drug Administration (FDA) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the Company’s operations and clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the Company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the Company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the Company in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com

Media Contact
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What milestone did Cue Biopharma announce on April 8, 2026 for CUE (Nasdaq: CUE)?

Cue announced a $7.5 million preclinical milestone payment tied to lead optimization approval. According to the company, Boehringer Ingelheim selected and approved the first compound, triggering the payment expected in May 2026.

When does Cue Biopharma expect to receive the $7.5 million payment for CUE?

The company expects to receive the payment in May 2026. According to the company, the payment follows Boehringer Ingelheim’s selection and approval of the first compound for lead optimization.

How much additional milestone and royalty potential does the Boehringer Ingelheim deal offer Cue (CUE)?

Cue is eligible for up to $337.5 million in additional research, development and commercial milestones plus royalties. According to the company, those payments are contingent on future milestones and net sales.

What program will Boehringer Ingelheim further develop under the collaboration with Cue (CUE)?

Boehringer Ingelheim will further develop CUE-501, a bispecific molecule intended for autoimmune and inflammatory diseases. According to the company, Cue’s technology will be leveraged to advance the candidate under the collaboration.

What does the milestone announcement mean for Cue’s lead asset CUE-401 (CUE)?

The announcement accompanies progress as CUE-401 moves toward the clinic. According to the company, the milestone underscores parallel advancement of CUE-401 and collaborative development of CUE-501.

Are the future payments from the Boehringer Ingelheim collaboration guaranteed for Cue (CUE)?

No, future payments are contingent on achievement of specified milestones and net sales. According to the company, eligibility exists for up to $337.5 million and royalty payments, but they depend on future outcomes.